Patents by Inventor Tzu-Lung Lin

Tzu-Lung Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220265754
    Abstract: The present invention provides a method of improving chronic obstructive pulmonary disease and obesity using traditional Chinese medicine polysaccharides and bacterial composition thereof.
    Type: Application
    Filed: February 18, 2022
    Publication date: August 25, 2022
    Inventors: Po-I Wu, Hsin-Chih Lai, Chia-Chen Lu, Tzu-Lung Lin
  • Publication number: 20220175821
    Abstract: The present invention provides methods of hypo-acylated lipopolysaccharide (LPS) for improving anti-oxidation and preventing/treating endotoxemia and diseases associated with endotoxemia.
    Type: Application
    Filed: October 27, 2021
    Publication date: June 9, 2022
    Inventors: HSIN-CHIH LAI, CHIA-CHEN LU, TZU-LUNG LIN, CHUN-HUNG LIN, CHENG-I DANIEL YAO, PO-I WU
  • Patent number: 11253541
    Abstract: The present invention describes a method of inhibiting inflammatory response by using a lipopolysaccharide of Parabacteroides goldsteinii. The lipopolysaccharide of Parabacteroides goldsteinii can effectively inhibit the immune responses caused by pathogenic lipopolysaccharides in peripheral blood mononuclear cells, macrophages, and/or B cells, and then can be effectively used to inhibit the inflammatory responses and the preparation of the related compositions.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: February 22, 2022
    Assignee: MULTISTARS BIOTECHNOLOGY COMPANY LIMITED
    Inventors: Tzu-Lung Lin, Po-I Wu
  • Patent number: 11147843
    Abstract: The present invention provides a method of preventing or treating obesity by administering the probiotic bacterium of a novel Parabacteroides goldsteinii strain to the subject in need. The novel Parabacteroides goldsteinii strain is derived from the gastrointestinal tract of an individual and has better aero-tolerance and better acid-tolerance therefore it has better environmental tolerance to adapt to different living environments. The novel Parabacteroides goldsteinii strain not only can effectively prevent the weight gain of the individual, but also can effectively slow down the weight gain of the obese individual; therefore, the novel Parabacteroides goldsteinii strain of the present invention can be used for preparing a pharmaceutical composition for prevention and/or treating obesity.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: October 19, 2021
    Assignee: MULTISTARS BIOTECHNOLOGY COMPANY LIMITED
    Inventors: Po-I Wu, Chih-Jung Chang, Yu-Ling Tsai, Tzu-Lung Lin
  • Publication number: 20210115478
    Abstract: The present invention provides a method for sorbitol production comprising: providing a Parabacteroides goldsteinii strain, cultivating the Parabacteroides goldsteinii strain in a suitable cultivation medium, and contacting the Parabacteroides goldsteinii strain with the hydrophobic substrate to form sorbitol to replace the disadvantages produced in industrial manufacturing. Because it is possible to control the production of sorbitol according to the demand by regulating the expression level of genes related to the production of sorbitol in the Parabacteroides goldsteinii, it enables sorbitol to be more effectively applied to products of a food, a medicine, or a skin care product.
    Type: Application
    Filed: January 21, 2020
    Publication date: April 22, 2021
    Inventors: Tzu-Lung Lin, Po-I Wu
  • Publication number: 20200237806
    Abstract: The present invention describes a method of inhibiting inflammatory response by using a lipopolysaccharide of Parabacteroides goldsteinii. The lipopolysaccharide of Parabacteroides goldsteinii can effectively inhibit the immune responses caused by pathogenic lipopolysaccharides in peripheral blood mononuclear cells, macrophages, and/or B cells, and then can be effectively used to inhibit the inflammatory responses and the preparation of the related compositions.
    Type: Application
    Filed: January 21, 2020
    Publication date: July 30, 2020
    Inventors: Tzu-Lung Lin, Po-I Wu
  • Publication number: 20200078414
    Abstract: The present invention provides a method of preventing or treating obesity by administering the probiotic bacterium of a novel Parabacteroides goldsteinii strain to the subject in need. The novel Parabacteroides goldsteinii strain is derived from the gastrointestinal tract of an individual and has better aero-tolerance and better acid-tolerance therefore it has better environmental tolerance to adapt to different living environments. The novel Parabacteroides goldsteinii strain not only can effectively prevent the weight gain of the individual, but also can effectively slow down the weight gain of the obese individual; therefore, the novel Parabacteroides goldsteinii strain of the present invention can be used for preparing a pharmaceutical composition for prevention and/or treating obesity.
    Type: Application
    Filed: September 3, 2019
    Publication date: March 12, 2020
    Inventors: Po-I Wu, Chih-Jung Chang, Yu-Ling Tsai, Tzu-Lung Lin
  • Patent number: 9938508
    Abstract: The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: April 10, 2018
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Jin Town Wang, Tzu Lung Lin
  • Patent number: 9755694
    Abstract: A “wall-embedded” power-line-communication (PLC) enabled device connecting with the home network backbone through the PLC technology is disclosed. The wall-embedded PLC enabled device includes at least a system module, a front panel, and a holder. With flexible, modular architecture, the device can easily optionally integrate required functions, such as sensors, actuators and so on, or additional heterogeneous communication interfaces, to extend the service coverage, to support the specific smart-house services, and other uses.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: September 5, 2017
    Assignee: ZyXEL communications Corp.
    Inventors: Tzung-Pao Chen, Tzu-Lung Lin, Chin-Ru Lin, Chen-Ju Lai
  • Publication number: 20170218344
    Abstract: The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.
    Type: Application
    Filed: February 21, 2017
    Publication date: August 3, 2017
    Inventors: Jin Town Wang, Tzu Lung Lin
  • Patent number: 9617314
    Abstract: The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 11, 2017
    Assignee: NATIONAL TAIWAN UNIVERSITY
    Inventors: Jin Town Wang, Tzu Lung Lin
  • Publication number: 20150155911
    Abstract: A “wall-embedded” power-line-communication (PLC) enabled device connecting with the home network backbone through the PLC technology is disclosed. The wall-embedded PLC enabled device includes at least a system module, a front panel, and a holder. With flexible, modular architecture, the device can easily optionally integrate required functions, such as sensors, actuators and so on, or additional heterogeneous communication interfaces, to extend the service coverage, to support the specific smart-house services, and other uses.
    Type: Application
    Filed: March 20, 2014
    Publication date: June 4, 2015
    Applicant: ZyXEL communications Corp.
    Inventors: Tzung-Pao Chen, Tzu-Lung Lin, Chin-Ru Lin, Chen-Ju Lai
  • Publication number: 20140295528
    Abstract: The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 2, 2014
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Jin Town Wang, Tzu Lung Lin
  • Patent number: 8110359
    Abstract: The present invention relates to a method of identifying a serotype of Klebsiella pneumoniae, in particular to a method using specific polymerase chain reaction (PCR) primer sets designed according to a fragment of a capsular polysaccharide synthesis (cps) region to identify a K57 or a NTUH-N1 serotype and its application. NTUH-N1 is a novel serotype which differs from the previously reported 77 serotypes. This PCR-based cps genotyping method not only solves the problems of insufficient specificity and sensitivity caused by conventional immune method, but can be applied in clinical diagnosis with the advantages of rapidity and low cost. In addition, the rate of unidentifiable strains can also be reduced by this method.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: February 7, 2012
    Assignee: National Taiwan University
    Inventors: Jin-Town Wang, Yi-Jiun Pan, Han-Chi Fang, Hui-Ching Yang, Tzu-Lung Lin, Pei-Fang Hsieh, Feng-Chiao Tsai, Yoav Keynan
  • Publication number: 20100136534
    Abstract: The present invention relates to a method of identifying a serotype of Klebsiella pneumoniae, in particular to a method using specific polymerase chain reaction (PCR) primer sets designed according to a fragment of a capsular polysaccharide synthesis (cps) region to identify a K57 or a NTUH-N1 serotype and its application. NTUH-N1 is a novel serotype which differs from the previously reported 77 serotypes. This PCR-based cps genotyping method not only solves the problems of insufficient specificity and sensitivity caused by conventional immune method, but can be applied in clinical diagnosis with the advantages of rapidity and low cost. In addition, the rate of unidentifiable strains can also be reduced by this method.
    Type: Application
    Filed: April 15, 2009
    Publication date: June 3, 2010
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Jin-Town Wang, Yi-Jiun Pan, Han-Chi Fang, Hui-Ching Yang, Tzu-Lung Lin, Pei-Fang Hsieh, Feng-Chiao Tsai, Yoav Keynan
  • Publication number: 20100129408
    Abstract: The present invention relates to a Klebsiella pneumoniae gene-deleted mutant and its producing methods. The main objective of this invention is to construct a Klebsiella pneumoniae tonB deletion mutant used as an immunogenically effective amount of a live attenuated vaccine against the community-acquired pyogenic liver abscess, where the tonB gene was deleted. The tonB deletion mutant maintained the structure of the capsular polysaccharide on cell membrane surface, and induced no disease on the mouse after injection. In addition, the tonB deletion mutants induced the immunity against pyogenic liver abscess caused by Klebsiella pneumoniae.
    Type: Application
    Filed: May 1, 2009
    Publication date: May 27, 2010
    Applicant: NATIONAL TAIWAN UNIVERSITY
    Inventors: Jin-Town Wang, Pei-Fang Hsieh, Tzu-Lung Lin, Cha-Ze Lee, Shih-Feng Tsai
  • Patent number: 7244603
    Abstract: Disclosed is a novel type II restriction endonuclease. Such enzyme recognizes a particular non-palindromic sequence of 5 oligonucleotides and cleaves DNA downstream of the DNA recognition sequence of nucleotides at the fourth base in the upper strand and the fifth base in the lower strand, and forms a one-base protruding end in the 5?-end after cleavage. The recognition and cleavage site of HpyC1I is identical to the known restriction endonuclease BccI respectively, but the nucleotide sequence and the amino acid sequence are different from any other know restriction enzymes.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: July 17, 2007
    Assignee: National Taiwan University
    Inventors: Jin-Town Wang, Tzu-Lung Lin
  • Publication number: 20050276476
    Abstract: A method of exposure compensation for simulating the dynamic of human eye comprises the following steps: sampling the brightness of an image; plotting a brightness level graph; converting the brightness level graph into a histogram of brightness; converting the histogram of brightness into a percentile diagram of brightness; converting the percentile diagram of brightness into a diagram of gamut curve; and replacing the gamut curve of the original image with the new gamut curve to obtain a modified image. Thereby, color level of the large part of low brightness can be raised to show the details of the image, and an excellent image quality is available.
    Type: Application
    Filed: June 9, 2004
    Publication date: December 15, 2005
    Inventor: Tzu-Lung Lin
  • Publication number: 20050202443
    Abstract: Disclosed is a novel type II restriction endonuclease. Such enzyme recognizes a particular non-palindromic sequence of 5 oligonucleotides and cleaves DNA downstream of the DNA recognition sequence of nucleotides at the fourth base in the upper strand and the fifth base in the lower strand, and forms a one-base protruding end in the 5?-end after cleavage. The recognition and cleavage site of HpyC1I is identical to the known restriction endonuclease BccI respectively, but the nucleotide sequence and the amino acid sequence are different from any other know restriction enzymes.
    Type: Application
    Filed: March 9, 2004
    Publication date: September 15, 2005
    Inventors: Jin-Town Wang, Tzu-Lung Lin
  • Patent number: D409775
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: May 11, 1999
    Inventor: Tzu-Lung Lin